Contact Us

CLINICAL TRIALS AT ADC MIDWEST

Learn about our CLINICAL TRIALS and find a trial that might be right for you.

  • ANCHOR STUDY

This study compares topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL).

CLOSED TO ENROLLMENT – RESULTS PENDING

  • FRANTZ VIRAL THERAPEUTICS STUDY

This study will evaluate the effectiveness of four 5-day cycles of artesunate suppositories in the treatment of HIV-negative individuals who have anal intraepithelial squamous lesions (anal HSIL).

OPEN ENROLLMENT – CONTACT US FOR MORE INFORMATION

  • AMC-103 STUDY

This phase II trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX- 3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Electroporation helps pores in your body’s cells take in the drug to strengthen your immune system’s response. Giving VGX-3100 and electroporation together may work better in treating patients with high- grade anal lesions.

OPEN ENROLLMENT – CONTACT US FOR MORE INFORMATION

Please note that acceptance into any study is dependent on full clinical evaluation as well as details of study status, both of which can only be fully evaluated at the time of a formal visit and screening.